Noroclav Tablets 500mg

Palatable tablet

This product is for the treatment of bacterial infections sensitive to clavulanic acid and amoxycillin in pre-ruminant calves and dogs. Clinically amoxycillin/clavulanic acid has been shown to be effective in treating a wide range of diseases of dogs including: Skin disease, soft tissue infections, dental infections, urinary tract infections respiratory disease and enteritis. In calves, amoxycillin/clavulanic acid has been shown to be effective in treating bacterial respiratory infections and enteritis. Active against a wide range of clinically important aerobic and anaerobic Gram positive and Gram negative bacteria.

For oral administration only. Calves: The recommended dose rate is 6.25-12.5mg/kg of combined active ingredients twice daily, which is provided by 1 tablet per 25-50kg bodyweight, twice daily. Use the higher dose rate for the initial dose, and for severely affected calves. Treatment should be continued until 12 hours after all symptoms have subsided. Amoxycillin given orally is inactivated in calves that have a functional rumen (i.e. from 6 weeks of age, if fed herbage or concentrates). Dogs: Tablets are often accepted from the hand. Alternatively, the tablets may be crushed and added to a little food. The standard dose rate is 12.5 mg/kg twice daily. Therapy should be continued for 5-7 days or for 48 hours after all symptoms have subsided. For the majority of infections the above dosage regime is effective. Refractory cases however, particularly those of the respiratory tract, have shown improved cure rates by doubling the dose to 25mg/kg bodyweight twice daily. Chronic or refractory cases: In these cases a longer course of treatment may be required to allow sufficient time for damaged tissue to repair. Based on clinical trials, the following durations are suggested: chronic skin disease 10–20 days, chronic cystitis 10–28 days and respiratory disease 8–10 days.

Potentiated Penicillin (Amoxycillin and Clavulanic Acid) is an antibiotic in the penicillin family and is considered highly important to human and animal health. The use of this antibiotic should only be for the minimum period needed to meet the clinical objective. Clinical response to this antibiotic should be monitored during treatment, and choice of therapy reviewed if clinical signs of disease persist, increase, or relapse. In the event of treatment failure, culture and sensitivity should be considered to determine an appropriate alternative therapy. Indiscriminate use of this antibiotic can contribute to the development of antibiotic resistance.